Navigation Links
Exercise may be best defense against heart disease

exercise are crucial factors. But according to the research finding published by the American Journal of Preventive Medicine, // it has been found that calorie intake may not be a major factor in causing death by heart disease.

The finding was based on a 17-year study of almost 9,790 Americans, who participated in the First National Health and Nutrition Examination Survey, a national study which was done from 1971 to 1975. The participants were grouped based on reports of caloric intake (low, middle, high), recreation exercise (least, moderate, most) and body mass index (normal, overweight, obese).

During 17 years of follow-up, 1,531 participants died of heart disease. Adjustment for BMI and physical activity was done and the researches found that caloric intake was unrelated to heart disease, while those who exercised more and ate more were both leaner and had less than half the cardiovascular disease mortality than did those who exercised less, ate less and were overweight. The difference in mortality rates was 55 percent.

The research finding highlights that expending energy through physical activity may be the key to cutting the risks of heart disease and living a longer, more healthful life. Concurrently the outcome of Heart disease was not determined by a single factor, but rather by a compound of behavioral, socioeconomic, genetic and clinical characteristics.

The most practical outcome of the study was for a focus on increased energy expenditure rather than reduced caloric intake as the most productive behavioral strategy by which to extend healthy life.


'"/>




Page: 1

Related medicine news :

1. Exercises reduce risks of cancers
2. Exercise lowers Risk of Ovarian Cancer
3. Exercise is necessary in daily life
4. Exercise for patients with cancer
5. Exercise therapy for fibromyalgia
6. Exercise has a undeniable effect on cholesterol
7. Exercise with music aids with lung disorders
8. Exercise helps with leg cramps
9. Exercise helps people with cramping leg pain
10. Kids not getting enough Physical Exercise
11. Moderate Exercise may not help prevent Heart Disease
Post Your Comments:
(Date:7/25/2008)... New program delivers immediate co...[24-hour telephone access to language interpreters...g multilingual solutions. , ...LLE® http://www.lle-inc.com/index.html [(Lan...ider of interpretation, translation, and language ...
(Date:7/25/2008)... The Drug Information Association ...ill host the Critical Path Initiative (CPI) on the...16; Bethesda, MD) and the Critical Path Transporte... Horsham, PA (PRWEB) July 25...mation Association (DIA)] and the Food and Drug Ad...
(Date:7/24/2008)...TON-SALEM, N.C. Researchers at Wake Forest Unive...-standing clinical belief that the hepatitis C vir...restore itself after HIV patients are treated with..., Hepatitis C (HCV) infection is more serious in...e, according to the Centers for Disease Control. I...
(Date:7/24/2008)...UTH, Minn., July 24 /PRNewswire-FirstCall/ -- ev3 ... to report its 2008 second quarter and,year-to-dat...second quarter,and year-to-date financial results ...ding hours., The company will host a conference c...m. Eastern Time) on Tuesday, July 29, 2008. ev3,ma...
Breaking Medicine News(10 mins):Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
...ors of All India Institute of Medical Sciences (AI...ll //in Lok Sabha on Thursday intensified with fiv...ike - Dr Anil Sharma, spokesman of the AIIMS Resid...the doctors would continue attending duty and serv...
...Ease Dietary Supplement, a product containing the ...ndent on it when used just for few months. // Est...which should be consumed only under a practitioner...r of side effects like loss of memory, confusion, ...
... wish-list of many scientists and sufferers the wo...–child of an //Australian scientist, whose perseve...th of cancer cells, seems to have paid off. Prof...king on his ‘baby’ for the past 20 years, may just...
...mptoms of high fever and bodyache has killed 12 ch...g to official sources, 12 children died in two or ...strict due to the disease commonly referred as 'kh...a dozen children were suffering from the same dise...
Other Medicine News:
(Date:7/24/2008)... Ortho-McNeil Neurologics, a,division of Ortho-McN...,that the U.S. Food and Drug Administration (FDA) ...topiramate), based on studies submitted in,respons...he use of TOPAMAX,in pediatric patients aged 1 to ...on to granting pediatric exclusivity, the FDA is c...
(Date:7/24/2008)...cology Patient Accrual, DENVER, July 24 /PRNewswi...anization (RMO), has contracted with five leading ...ite management services for their,clinical trials ...The new,trials include the following disease indic...tic Breast Cancer, Metastatic Sarcoma, Chronic Mye...
(Date:7/23/2008)... print edition of Clinical Ch.../- A Roche Diagnostics-sponsored,pilo...e natriuretic peptide,(NT-proBNP) confirms the pot...in predicting the risk of cardiovascular adverse e...al anti-inflammatory drugs of,the COX inhibitor cl...
(Date:7/23/2008)...Code BioPharmaceutics, Inc.,an emerging biopharma...,results demonstrating the utility of their lead d...chronic blood disorder paroxysmal nocturnal,hemogl...nted at the XXII,International Complement Workshop...only treatment currently available for PNH patient...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 1Glowing films developed by UC San Diego chemists reveal traces of explosives 3416 2Origin of cells for connective tissues of skull and face challenged 3415 1Origin of cells for connective tissues of skull and face challenged 3415 2Origin of cells for connective tissues of skull and face challenged 3415 3Journal of Ultrasound In Medicine features bioeffects consensus report 20179 1Graduates Forced to Join Millions of Uninsured Americans 20174 1Graduates Forced to Join Millions of Uninsured Americans 20174 2Graduates Forced to Join Millions of Uninsured Americans 20174 3
...007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today an... evaluating the company,s once-daily,anti-HIV drug...r,DF) 300 mg as a potential treatment for chronic ... efficacy endpoint. The study shows,that Viread is...l,drug Hepsera(R) (adefovir dipivoxil) among patie...
...-FirstCall/ --,NeurogesX, Inc. announced today the...se 3 trial in postherpetic neuralgia (PHN).,Misha-... University,of Wisconsin in Madison and lead acade...present the results of the study in a,June 8 poste...Neuropathic Pain in Berlin, Germany. Dr. Backonja,...
Other Medicine Technology:Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 2NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 3NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG) 4
...eeds I-125 are brachytherapy sources which are imp...mors, especially in the prostate. The seeds remain...ic effect, i.e. after radioactive decay is complet...ey are supplied in a sterile form. Isoseeds I-125 ...
...mirrors for complete anterior chamber angle viewin...or easy handling and stability. Choice large or sm...llows static or dynamic gonioscopy without methylc... coating protects mirrors and is compatible with m...
Three mirrors of 64, 67 and 73 and a small diameter contact surface for use without methylcellulose. The fundus can be viewed through the central axis of the lens. Multi-layer polymer coating protect
West lacrimal cannula blunt tip with side port.
Medicine Products: